Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer

Part of paid clinical trials in Rochester, Minnesota.

Sponsor
Mayo Clinic
Study ID
NCT04703244
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • chemotherapy or endocrine therapy for breast cancer — PROCEDURE
    Collect blood and leftover surgical tissue from patients with breast cancer remaining after chemotherapy or endocrine therapy is completed.

Study Details

Breast cancer patients who undergo neoadjuvant systemic therapy and have residual breast cancer identified at the time of surgery exhibit a high (\>50%) risk of future life-threatening recurrences and death.

Key Dates

Start date
Jan 13, 2021
Status verified
Feb 2026
Primary completion
Jan 15, 2041
Completion
Jan 15, 2042

Study Design

Enrollment
999 participants (estimated)

Primary Outcome Measure

Generate patient derived xenografts (PDX) and organoids from breast cancer patients with residual disease after neoadjuvant therapy [ Time Frame: Up to 12 months until death or a maximum of 20 years post registration ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Mayo ClinicRochesterMinnesota55905
Clinical Trials Referral Office
[email protected]
855-776-0015
Judy C. Boughey, M.D. (PRINCIPAL_INVESTIGATOR)
Matthew P. Goetz, M.D. (PRINCIPAL_INVESTIGATOR)

Find similar trials in Rochester, MN

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
Mayo Clinic· Rochester, MN

Related Studies